Literature DB >> 1253171

Alkylating properties of phosphoramide mustard.

M Colvin, R B Brundrett, M N Kan, I Jardine, C Fenselau.   

Abstract

The relative alkylating activities of two of the cytotoxic metabolites of cyclophosphamide, phosphoramide mustard and nornitrogen mustard, have been studied at pH 4.6 and 7.4. The products formed on alkylation of ethanethiol by these metabolites have been identified, confirming that phosphoramide mustard undergoes alkylation reactions as an intact molecule. Deuterated analogs of the two metabolites have been synthesized, namely N,N-bis(2,2-dideutero-2-chloroethyl)-phosphorodiamidic acid and N,N-bis(2,2-dideutero-2-chloroethyl)amine and used to determine that alkylation proceeds directly via an aziridinium intermediate rather than a direct SN2 displacement of the chlorine atom.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253171

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Prodrugs for the improvement of drug absorption via different routes of administration.

Authors:  L P Balant; E Doelker; P Buri
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide.

Authors:  E J Valente; K K Chan; K L Servis
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

4.  The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.

Authors:  M D Bacolod; S M Lin; S P Johnson; N S Bullock; M Colvin; D D Bigner; H S Friedman
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

Review 6.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

7.  Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

Authors:  U Niemeyer; J Engel; G Scheffler; K Molge; D Sauerbier; W Weigert
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeutics.

Authors:  Catherine Silvestri; Jennifer S Brodbelt
Journal:  Mass Spectrom Rev       Date:  2012-11-13       Impact factor: 10.946

Review 10.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.